CRISPR CMO buys 1,508 shares in Form 4

CRISPR Therapeutics’ Chief Medical Officer, Naimish Patel, reported buying 1,508 common shares at $32.96 each on April 3, 2025.

Rhea-AI Filing Summary

CRISPR Therapeutics’ Chief Medical Officer, Naimish Patel, reported buying 1,508 common shares at $32.96 each on April 3, 2025. This direct ownership transaction brought his total reported holdings to 1,508 shares.

The filing notes this purchase was matchable under Section 16(b) with a later sale of 1,508 shares at $35.94 per share on May 29, 2025 under a mandatory “sell to cover” for a vested restricted stock unit. Patel agreed to pay CRISPR Therapeutics $4,493.84, equal to the full short-swing profit.

Insider Trade Summary

Net Buyer: 1,508 shares

Net Buy 1 txn

Insider Patel Naimish

Role Chief Medical Officer

Bought 1,508 shs ($50K)

Type	Security	Shares	Price	Value
Purchase	Common Shares	1,508	$32.96	$50K

Holdings After Transaction: Common Shares — 1,508 shares (Direct)

Footnotes (1)

1. F1. The purchase of Common Shares reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of 1,508 shares, with a subsequent sale of Common Shares at a price of $35.94 per share on May 29, 2025 pursuant to a mandatory "sell to cover" provision in an award agreement covering a restricted stock unit that vested on such date (and which was reported on a separate Form 4 filing dated May 30, 2025). The Reporting Person has agreed to pay to the Issuer $4,493.84, representing the full amount of the profit realized in connection with the short-swing transaction.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did CRISPR Therapeutics (CRSP) report for Naimish Patel?

CRISPR Therapeutics’ Chief Medical Officer, Naimish Patel, bought 1,508 common shares. The purchase occurred on April 3, 2025 at a price of $32.96 per share, resulting in directly owned holdings of 1,508 shares reported on this Form 4 filing.

At what price did CRSP’s Chief Medical Officer purchase shares on April 3, 2025?

Naimish Patel purchased CRISPR Therapeutics shares at $32.96 each. The Form 4 shows he acquired 1,508 common shares in a direct ownership transaction on April 3, 2025, establishing a reported total position of 1,508 directly held shares after the transaction.

How many CRISPR Therapeutics (CRSP) shares did Naimish Patel own after the reported transaction?

After the transaction, Naimish Patel was reported as owning 1,508 shares. The Form 4 indicates his April 3, 2025 purchase of 1,508 common shares brought his directly held beneficial ownership to 1,508 CRISPR Therapeutics shares.

What short-swing profit repayment is disclosed in this CRSP Form 4 filing?

The filing discloses a short-swing profit repayment of $4,493.84. The purchase of 1,508 shares at $32.96 was matched with a later sale at $35.94, and Naimish Patel agreed to pay CRISPR Therapeutics the full profit amount under Section 16(b).

How does the CRSP Form 4 describe the later share sale related to this purchase?

The later sale involved 1,508 shares at $35.94 per share. It occurred on May 29, 2025 under a mandatory “sell to cover” provision tied to a restricted stock unit vesting, with details reported on a separate Form 4 filed on May 30, 2025.

What is the role of Naimish Patel at CRISPR Therapeutics (CRSP) in this Form 4?

Naimish Patel is identified as CRISPR Therapeutics’ Chief Medical Officer. The Form 4 lists him as an officer, not a director or 10% owner, and reports his direct purchase of 1,508 common shares along with the related short-swing profit repayment agreement.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/27/2026 - 05:35 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Patel Naimish

(Last) (First) (Middle)

C/O CRISPR THERAPEUTICS

105 WEST FIRST STREET

(Street)

BOSTON MA 02127

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CRISPR Therapeutics AG [ CRSP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
04/03/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	04/03/2025		P(1)		1,508	A	$32.96	1,508	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The purchase of Common Shares reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of 1,508 shares, with a subsequent sale of Common Shares at a price of $35.94 per share on May 29, 2025 pursuant to a mandatory "sell to cover" provision in an award agreement covering a restricted stock unit that vested on such date (and which was reported on a separate Form 4 filing dated May 30, 2025). The Reporting Person has agreed to pay to the Issuer $4,493.84, representing the full amount of the profit realized in connection with the short-swing transaction.

	/s/ Naimish Patel	01/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.